I think it's a fair assessment with $1.5b max with any pharma carrying the cost of clinical trials and commercialization of Bril without the phase II commencing yet. Bril will be fast-tracked for CV19.
$600mil now and another 900mil as contingent value rights (CVR). Any funding or grants plus PII will push the cash upfront and CVR higher. As of right now, getting a $1.5b cash only after funding and grant could happen too. TAGB is betting on Bril and Leo!
News 
Market Data 
Discover 
